CLP 102: ICI LUNG CANCER PRECEPTORSHIP

Multidisciplinary management, standards of care, optimal diagnostics, therapies, and future perspectives in the care of Lung Cancer patients in sub-Saharan Africa incorporating Biosimilars.

Eldoret, Kenya

Training Start Date Jan/March 2021: To be confirmed once the class size of 20-30 participants is met

Training Duration: 6 weeks

Course Director: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist Executive

Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com Website: www.intercancer.com

Lead Course Faculty: TBN

Course Coordination: Dr. Chizi Kiti

Head, Office of Education and Training

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: ckiti@intercancer.com Website: www.intercancer.com

This educational activity is provided independently by the International Cancer Institute (ICI)

through an educational grant from Pfizer

Accreditation of this course is by KMPDC, KPPB, NCK and COC

Target Audience

The primary target audience for this course comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; cardiothoracic surgeons; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.

Statement of Need

General internists, specialist health care professionals and Primary Care Clinicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. International Cancer Institute’s Preceptorship Courses aims to leverage the expertise of its Faculty to help clinicians understand best practices in diagnosis and management of conditions encountered in the clinical setting in sub-Saharan Africa.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. To learn about lung cancer data in Kenya and sub-Saharan Africa (SSA)
2. To learn about the evidence-base for lung cancer screening
3. To understand diagnostic modalities including the role of Biopsies / Re-Biopsies / Liquid Biopsy in Patients with NSCLC
4. To learn about the TNM staging and the different subtypes of NSCLC
5. To understand the different treatment strategies in NSCLC
6. To learn about the management of early stage Non-Small-Cell Lung Cancer and the use of adjuvant treatments
7. To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
8. To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC (Personalized Therapies)
9. To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
10. To learn about the systemic treatment of mesothelioma and SCLC
11. To learn about the role of supportive and palliative care for lung cancer
12. To discuss the role and integration of Biosimilars in lung cancer management
13. Appreciate the Research priority areas in Lung cancer in SSA

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program

LECTURES

1. Orientation to the course
2. Lung Cancer Data in Kenya and SSA
3. Lung Cancer Prevention, Screening and Early detection
4. Lung Cancer Diagnostics & Pathology
5. Role of Imaging in Lung Cancer Management
6. NSCLC staging and Treatment
7. SCLC staging and Treatment
8. Role of surgery in the management of Lung Cancer
9. Role of Radiotherapy in the management of lung cancer
10. Mesothelioma
11. Lung Cancer Bench to Bedside: Now and Future Personalized therapies
12. Supportive and Palliative care in Lung Cancer
13. Biosimilars in Lung cancer Management
14. Research priorities & Clinical Trial Opportunities in Lung Cancer in SSA

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnership with the International Cancer Institute. Apply for sponsorship during the registration of the course

 If you have any questions or queries please send an email to education@intercancer.com

or director@intercancer.com

For more information visit our website www.intercancer.com

International Cancer Institute (ICI) ©2021

Your Partner in Cancer Control in SSA